Tenax Therapeutics, formerly Oxygen Biotherapeutics, is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care patients. The Company's main product is levosimendan, which is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand.